Home Services Commercial Partership Work with us Contact us THERAPEUTIC AREAS Anesthesia Asthma and allergic rhinitis Cardiometabolic Dermatology Migraine Hepatitis C HIV / AIDS Immunology Bacterial and fungal infections Oncology Osteoarticular Women's health CARDIOVASCULAR DISEASES 60 years, 40 drugs, 1,000 scientists: with these numbers we intend to defeat cardiovascular disease, still the leading cause of death in the world today. Coronary artery disease, stroke, and diabetes kill millions of people every year. Our commitment to coronary heart disease such as heart attack, angina pectoris, stroke and heart failure began in the 1950s and continues today. At a time when other major companies shift their focus away from this therapeutic area, MSD's commitment to cardiovascular health continues to increase. Also for this reason our company was awarded the prestigious award of "Best Cardiovascular Pipeline" by the US magazine R&D Directions, HYPERCHOLESTEROLEMIA High blood cholesterol levels are associated with an increased risk of incurring dangerous cardiovascular events. Research and Development activities in this area are part of our DNA: starting from the 70s, with the first agents capable of lowering blood cholesterol levels, up to the present day, with innovative drugs that have written the history of the therapy of dyslipidemias, as the first inhibitor of intestinal cholesterol absorption, awarded in 2006 with the prestigious Galen Prize for pharmaceutical innovation. The results of an important international study (IMPROVE IT) conducted on 18,144 patients have shown for the first time how this non-statin therapy significantly reduces major cardiovascular events in patients with acute coronary syndrome. HYPERTENSION High blood pressure is one of the most common diseases in industrialized countries, but many people who suffer from it are unaware that they have high blood pressure and, in many cases, discover that they are hypertensive only during a medical check-up. Furthermore, among those who are aware of it, only 25% manage to reach the recommended blood pressure values. In the past it was thought that hypertension was linked to aging, but today we know that it is not so and that hypertension does not spare young and very young people. There are many factors that contribute to the development of this pathology: genetic factors, age, diet, sedentary life but also smoking, alcohol abuse and stress. MSD has always been close to its patients: our products of the sartan class and ACE inhibitors can ensure complete therapy, combining blood pressure relief with 360 ° protection of the organs. We do not only want to restore normal blood pressure, but also to improve their quality of life. DIABETES In mid-2000 the company also entered the metabolic area, developing and marketing important innovative molecules for the treatment of type 2 diabetes and giving life to the first molecule in the class of DPP4 inhibitors. This new class of drugs improves glycemic control by improving the glycemic response of beta cells to glucose, i.e. by stimulating the biosynthesis and release of insulin and at the same time decreasing glucagon levels. Furthermore, having a glucose-dependent mechanism, it reduces the risk of hypoglycemia. In 2015 the results of the TECOS cardiovascular safety study, conducted on over 14,000 patients, confirmed that sitagliptin is not associated with any increase in cardiovascular risk. Today it is estimated that in Italy there are about 4 million patients affected by this pathology. We want people to lead healthier lives not only through our medications, but also through educational and information programs for doctors and patients. Since 2008 MSD Italia has undertaken the La Dolce Vita project, in collaboration with the excellence of diabetology and gender medicine, in particular AMD, ADI, FAND, SID and SIMG, with the aim of raising awareness among the Italian scientific community, institutions and patients on the importance of a correct lifestyle and diet. As a guarantee of the quality of our services, the scientific representatives of this line have obtained the prestigious certification of the SIF, the Italian Society of Pharmacology. Information Products Sites for the public Devote yourself to diabetes Sites for healthcare professionals Inegy - Ezetrol Januvia - Janumet Sinvacor Financial info Actions Annual report The MSD Manuals Italian edition American Edition Handbook of Geriatrics Pressroom Releases Contacts Our publications Publications Talk Copyright © 2012 MSD Italia Srl All rights reserved. VAT number 00887261006 CORP-1187907-0000-MSD-W-07/2018 Privacy Terms and conditions